We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02576301
Title Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Acronym AML
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OXiGENE
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
David Geffen School of Medicine at UCLA RECRUITING Los Angeles California 90095 United States Details
University of Florida RECRUITING Gainesville Florida 32610 United States Details
University of Miami Sylvester Comprehensive Cancer Center RECRUITING Miami Florida 33136 United States Details
University of Kansas Cancer Center and Medical Pavilion RECRUITING Westwood Kansas 66205 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field